Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Parkinson’s Foundation Adds Alison Herman to its Board of Directors

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

“Alison brings a proven ability to engage the philanthropic community of the Parkinson’s Foundation in funding research that helps improve the lives of people with the disease. I have known Alison for more than 30 years and am extremely impressed with her passion for our cause,” said John W. Kozyak, Esq., chairman of the board of the Parkinson’s Foundation. “We are proud to welcome Alison to our Board.”

Herman joined Southern Glazer’s in 2008 and currently focuses on regulatory and compliance matters in the 44 states where Southern Glazer’s operates. Prior to that, she served 14 years as attorney at Breier Seif Herman & Silverman, P.A., specializing in corporate acquisitions, retirement plans, distribution agreements, private foundations, tax and estate planning. Leveraging her experience, Herman has been instrumental in assisting the Parkinson’s Foundation Wines on the Bay event. Herman received a law degree from the University of Miami School of Law.

“It is an honor to join the Parkinson’s Foundation board and a great privilege to serve its community of those who are living with the disease,” Herman said. “Seeing a close family member affected by Parkinson’s gives me great resolve in the Foundation’s mission to make life better for people with Parkinson’s.”

A complete list of the Parkinson’s Foundation’s Board of Directors is available at www.parkinson.org/board.

###

About the Parkinson’s Foundation
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. For more information, visit www.parkinson.org or call (800) 4PD-INFO (473-4636).

About Parkinson’s Disease
Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression, as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

 

Tuesday, May 8, 2018
Update on Tozadenant Trial for Parkinson’s
Thursday, November 16, 2017

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial A research study in humans that aims to test a new intervention – this could be a drug, surgery or therapy like exercise or diet guidelines – to make sure it is effective and safe..

Parkinson’s Foundation Adds Marcia Mondavi Borger to Board of Directors
Tuesday, November 14, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Marcia Mondavi Borger to its Board of Directors.

Parkinson’s Foundation and Melvin Yahr International Parkinson’s Disease Foundation Announce Merger
Thursday, October 26, 2017

Parkinson’s Foundation Establishes ‘Dr. Melvin Yahr Research Award’ to Fund Neurology Fellows, Promote Leadership Diversity in Parkinson’s Research

Parkinson’s Foundation Welcomes Two New Board Members
Tuesday, October 24, 2017

Peter Goldman and Joshua Raskin Join Board of Directors

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Chicago entrepreneur Peter Goldman and New York financial analyst Joshua Raskin to its Board of Directors.

Parkinson's Foundation Unveils New Brand and Website
Thursday, October 19, 2017

NEW YORK and MIAMI /PRNewswire-USNewswire/ — The Parkinson's Foundation today announced the launch of its new brand and website following the recent merger of two legacy organizations – National Parkinson Foundation and Parkinson's Disease Foundation – as part of its mission to

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia
Friday, August 25, 2017

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

Parkinson’s Foundation Announces $1.2 Million Investment to Advance Careers, Support Innovation of Early Career Parkinson’s Scientists
Tuesday, August 8, 2017

NEW YORK & MIAMI The Parkinson's Foundation is pleased to announce a $1.2 million investment in 27 career development and fellowship grants to support the work of promising early career scientists in the field of Parkinson's.

Parkinson’s Foundation Announces New Podcast With Research, Findings And Advice For Patients, Healthcare Professionals, And General Community
Tuesday, August 1, 2017

'Substantial Matters: Life and Science of Parkinson's' Podcast Now Available Online

Parkinson’s Foundation Appoints Sean Kramer as Chief Development Officer
Tuesday, July 11, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced its hiring of Sean Kramer as Senior Vice President, Chief Development Officer. The noted non-profit leader will oversee fundraising initiatives for the national organization, working from its offices in New York and Miami.

The Parkinson’s Foundation’s Fall Moving Day® Walks Fund Local Parkinson’s Programs
Thursday, June 8, 2017

Seven Cities Receive Community Grants 

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.